Mucormycosis in a crohn's disease patient treated with infliximab

Digestion

Volumn 80, Issue 3, 2009, Pages 182-184

  Wall, Geoffrey C ^a   Leman, Bernard I ^a  

^a DRAKE UNIVERSITY   (United States)

Author keywords

Crohn's disease; Infliximab; Mucormycosis

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AZATHIOPRINE; INFLIXIMAB; POSACONAZOLE;

ADULT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DEBRIDEMENT; DIABETES MELLITUS; DRUG WITHDRAWAL; ENDOSCOPY; FACE PAIN; FEMALE; FEVER; FUNGUS GROWTH; GASTROESOPHAGEAL REFLUX; HUMAN; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LOW DRUG DOSE; MUCORMYCOSIS; PRIORITY JOURNAL; SINUSITIS; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MUCORMYCOSIS; SINUSITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349264455     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000230676     Document Type: Article

References (17)

1. Travis SP, Stange EF, Lémann M, et al: European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55(suppl 1): i16-i35.
2. Hansen RA, Gartlehner G, Powell GE, Sandler RS: Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007; 5: 729-735.
3. Reddy JG, Loftus EV Jr: Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006; 35: 837-855.
4. Alderson JW, Van Dinter TG Jr, Opatowsky MJ, Burton EC: Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. MedGen Med 2005; 7: 7.
5. Spellberg B, Edwards J Jr, Ibrahim A: Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-569.
6. Tehmeena W, Hussain W, Zargar HR, Sheikh AR, Iqbal S: Primary cutaneous mucormycosis in an immunocompetent host. Mycopathologia 2007; 164: 197-199.
7. Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D'Souza O: Rhinoorbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003; 51: 231-236.
8. Brown J: Zygomycosis: an emerging fungal infection. Am J Health Syst Pharm 2005; 62: 2593-2596.
9. Chayakulkeeree M, Ghannoum MA, Perfect JR: Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 25: 215-229.
10. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL: The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27: 1138-1147.
11. Marty FM, Cosimi LA, Baden LR: Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-952.
12. American Diabetes Association: Standards of medical care in diabetes - 2008. Diabetes Care 2008; 31:S12-S54.
13. Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
14. Singh P, Taylor SF, Murali R, Gomes LJ, Kanthan GL, Maloof AJ: Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor. Clin Experiment Ophthalmol 2007; 35: 275-280.
15. Gadadhar H, Hawkins S, Huffstutter JE, Panda M: Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy. J Clin Rheumatol 2007; 13: 361-362.
16. Devlin SM, Hu B, Ippoliti A: Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. Dig Dis Sci 2007; 52: 2078-2081.
17. Odessey E, Cohn A, Beaman K, Schechter L: Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation. Surg Infect 2008; 9: 91-98.